drugset / Trial / NCT00203320
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
Timeline
- Start
- 2005-04
- Primary completion
- —
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | — | Other |